[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-associated-pneumonia-sap\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-associated-pneumonia-sap":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641225","oropharyngeal-flushing-suction-tube-with-laryngoscope-for-stroke-associated-pneumonia-100641225",false,"NCT07647666","Oropharyngeal Flushing Suction Tube With Laryngoscope for Stroke-Associated Pneumonia","Translational Application of an Oropharyngeal Flushing Suction Tube Combined With Laryngoscope for Improving Prognosis in Stroke-Associated Pneumonia: A Prospective Randomized Controlled Trial","OFST-SAP","Inclusion Criteria:\n\n1. Confirmed acute ischemic stroke by cranial CT or MRI.\n2. Age 18 years or older.\n3. Glasgow Coma Scale score of 6 to 12.\n4. No artificial airway and no requirement for invasive mechanical ventilation at enrollment.\n5. Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Existing artificial airway or invasive mechanical ventilation at ICU admission or screening.\n2. Pre-existing pulmonary infection at enrollment, or definite extra-pulmonary organ or tissue infection during the study period.\n3. Hemorrhagic blood disorder, clinically significant coagulopathy, or bleeding risk precluding laryngoscopy.\n4. Oral or maxillofacial deformity impeding laryngoscope insertion.\n5. Cervical spine fracture, atlantoaxial instability, or other condition restricting neck extension or movement.\n6. Confirmed or suspected pregnancy.\n7. Irreversible critical illness with anticipated survival less than 28 days.\n8. Uncontrolled hypertension or recurrent malignant arrhythmias.\n9. Other conditions judged by investigators to make participation unsuitable.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Stroke-associated pneumonia is a common and clinically important complication after acute ischemic stroke, especially in non-intubated patients with impaired consciousness and reduced cough or swallowing reflexes. Conventional oral or nasal suction may be insufficient for removing deep oropharyngeal secretions. This prospective randomized controlled trial will evaluate whether a patented oropharyngeal flushing suction tube combined with direct laryngoscopy reduces the 28-day incidence of stroke-associated pneumonia compared with laryngoscope-guided standard suction and conventional oral\u002Fnasal suction.",[27,28],"Acute Ischemic Stroke","Stroke-Associated Pneumonia (SAP)",[30,31,32,33,34],"Oropharyngeal Suction","Laryngoscope","Airway Management","Suction Tube","Aspiration Pneumonia","NOT_YET_RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2029-07-31",{"name":45,"class":46},"Shanghai Pudong New Area Gongli Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100633557","phase-1-an-open-label-dose-escalation-study-on-the-safety-tolerability-and-preliminary-efficacy-for-preventing-sap-by-intravenous-pump-delivered-propranolol-in-patients-with-ich-100633557","NCT07528235","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage","PROCHASE-DoE","Inclusion Criteria:\n\n* Patients aged \\> 18 and ≤ 80 years of age;\n* Can be treated with the study drug within 24 h of symptom onset;\n* No fever or infection was observed upon admission;\n* NIHSS score ≥10;\n* Supratentorial parenchymal haematoma (≥10 mL);\n* GCS score ≥ 6;\n* Patients or their family members sign informed consent forms.\n\nExclusion Criteria:\n\n* Infections within the last 4 weeks;\n* Use of antibiotics within the last 2 weeks;\n* Known pre-ICH dysphagia;\n* Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;\n* Previous disability with pre-ICH mRS score ≥ 2;\n* Brainstem hemorrhage;\n* Life expectancy less than 14 days;\n* Death appeared imminent;\n* Pregnancy or within 30 d of delivery;\n* Previous use (within 1 month) of β-blockers or reserpine;\n* Bronchial asthma or COPD;\n* Cardiogenic shock;\n* Degree II-III atrioventricular blocks;\n* Severe or acute heart failure;\n* Heart rate \\\u003C 65 beats\u002Fmin;\n* Known to be allergic to propranolol;\n* Severe liver or renal insufficiency;\n* History of malignant tumors;\n* Currently participating in other interventional clinical trials;\n* Currently, immunosuppressants and immunotherapies are being administered.","10 Years","80 Years",{"count":59,"type":21},30,[61],"PHASE1","This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.",[64,28],"Intracerebral Hemorrhage",[66,64,67,68],"Propranolol","Stroke-Associated Pneumonia","Dose-Escalation Study","2026-04-07",{"date":71,"type":39},"2026-04-14",{"date":73,"type":21},"2026-05-01",{"date":75,"type":21},"2026-11-01",{"name":77,"class":46},"Tang-Du Hospital"]